ACC2023｜重磅研究日程公布！5个LBCT专场、3个FCR专场，您最关注哪些研究？

2023年3月4-6日，2023年美国心脏病学会年会暨世界心脏病学大会（ACC.23/WCC）将在美国新奥尔良以线上线下结合形式举办。本次年会依旧设置5个Late-Breaking Clinical Trials（LBCT）专场和3个Featured Clinical Research（FCR）专场，预计将公布38项研究结果（LBCT 23项，FCR 15项）。日前，ACC官网已公布相关日程，严道医声网特别进行整理，供广大读者参考。

届时，严道医声网将持续跟踪报道，并邀请专家进行解读，其余最新资讯邀您持续关注。

声明：严道医声网致力于传播权威、前沿的学术信息，及时将领域时事、前沿学术内容传递至国内，各项内容资料版权均归ACC.23/WCC所有，如有涉及版权等问题，请第一时间与我们联系。

Late-Breaking Clinical Trials（LBCT）

LBCT Ⅰ

北京时间：3月4日11:30PM-12:30AM

1.Bempedoic Acid And Cardiovascular Outcomes In Statin Intolerant Patients At High Cardiovascular Risk

1.心血管高风险的他汀类药物不耐受人群中贝培多酸和心血管结局的关系

2.TRILUMINATE Pivotal: A Landmark Randomized Clinical Trial Of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation

2.TRILUMINATE Pivotal：一项经导管三尖瓣缘对缘修复三尖瓣反流的标志性随机临床试验

3.Statins To Prevent The Cardiotoxicity From Anthracyclines: The STOP-CA Trial

3.STOP-CA试验：他汀类药物用于预防蒽环类药物的心脏毒性

LBCT Ⅱ

北京时间：3月5日10:00PM-11:15PM

4.Minimally Invasive Versus Conventional Sternotomy For Mitral Valve Repair Surgery: An Expertise Based Multicentre Randomised Controlled Trial (UK Mini Mitral)

4.二尖瓣修复手术中微创与常规胸骨切开的比较：一项基于专业的多中心随机对照试验（UK Mini Mitral）

5.Intravascular Imaging-guided Versus Angiography-guided Procedural Optimization In Complex Percutaneous Coronary Intervention

5.复杂经皮冠脉介入治疗中血管内成像引导与血管造影引导的手术优化比较

6.Transcatheter Edge-to-edge Repair Of Functional Mitral Regurgitation In Heart Failure: Final Five-year Results From The COAPT Trial

6.功能性二尖瓣反流心衰中的经导管缘对缘修复：COAPT试验的最终五年结果

7.Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients At Low Surgical Risk: 3-year Outcomes From The Evolut Low Risk Trial

7.低手术风险主动脉瓣狭窄患者行经导管或外科主动脉瓣置换术：Evolut Low Risk试验的3年结果

8.Complete Revascularization Strategies In Patients Presenting With Acute Coronary Syndromes And Multivessel Coronary Disease

8.急性冠脉综合征合并多支血管病变的完全血运重建策略

LBCT III 

北京时间：3月5日11:45PM-1:00AM

9.Building Electronic Tools To Enhance And Reinforce CArdiovascular REcommendations For Heart Failure (BETTER CARE-HF): A Pragmatic, Cluster-randomized Trial Comparing Two Ambulatory Clinical Decision Support Tools

9.构建电子工具以加强心力衰竭的心血管推荐（BETTER CARE-HF）：一项比较两种动态临床决策支持工具的实用群组随机试验

10.A Nationwide Randomized Trial Of Electronically Delivered Nudges To Increase Influenza Vaccination Uptake: The NUDGE-FLU Trial

10.一项全国范围内的随机试验NUDGE-FLU：网络推送用于增加流感疫苗接种率

11.A Randomized Trial Of A Personalized Clinical Decision Support Intervention To Improve Statin Prescribing In Patients With Atherosclerotic Cardiovascular Disease (PCDS Statin)
11.个性化临床决策支持干预用于改善动脉粥样硬化性心血管疾病患者他汀类药物使用的随机试验：PCDS Statin12.Translating Polygenic Risk For Coronary Artery Disease Into Clinically Actionable Information Using Causal A.I

12.使用因果AI将冠心病的多基因风险评分用于指导临床实践

13.A Randomized Trial Assessing The Impact Of Eliminating Copayment For High Value Preventive Medications For Low-income Seniors With Cardiovascular-related Chronic Diseases

13.一项评估在患有心血管相关慢病的低收入老年人消除高价值预防性药物的共同支付的影响的随机试验

LBCT Ⅳ

北京时间：3月6日10:30PM-11:45PM

14.Pulsed Field Ablation Treatment In Paroxysmal And Persistent Atrial Fibrillation Patients: Acute And Long-term Outcomes From The Pulsed Af Pivotal Trial

14.阵发性和持续性心房颤动患者的脉冲消融治疗：Pulsed Af关键试验的短期和长期结果

15.Impact Of Heart Failure Management Using Thoracic Fluid Monitoring From A Novel Wearable Sensor: Results Of The Benefits Of Microcor (μCor™) In Ambulatory Decompensated Heart Failure (BMAD) Trial

15.使用新型可穿戴传感器进行胸水监测对心力衰竭管理的影响：Microcor（μCor™) 用于活动性失代偿心力衰竭（BMAD）的临床试验

16.A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction

16.腕戴式经皮肌钙蛋白I传感器评估急性心肌梗死的新突破

17.Efficacy And Safety Of Macitentan Tadalafil Fixed Dose Combination In Pulmonary Arterial Hypertension: Results From The Randomized Controlled Phase III A DUE Study

17.马西替坦和他达拉非固定剂量联合治疗肺动脉高压的疗效和安全性：来自随机对照III期A DUE研究的结果

18.Coordinating Cardiology Clinics Randomized Trial Of Interventions To Improve Outcomes (COORDINATE) - Diabetes: Primary Results

18.协调心血管干预的随机试验以改善结果（COORDINATE）：糖尿病中的主要结果

LBCT Ⅴ

北京时间：3月7日1:00AM-2:15AM

19.Vigorous Exercise In Individuals With Hypertrophic Cardiomyopathy (HCM): Primary Results Of The Prospective, Multinational Lifestyle And Exercise In HCM (LIVE-HCM) Study

19.肥厚型心肌病（HCM）中的剧烈运动：HCM中的生活方式和运动（LIVE-HCM）的前瞻性国际多中心研究的主要结果

20.Return-to-play For Elite Level Athletes With Sudden Cardiac Death Predisposing Genetic Heart Diseases

20.具有心脏猝死风险的遗传性心脏病的专业运动员重返赛场

21.Anticoagulation Strategies In Non-critically Ill Hospitalized Covid-19 Patients: Principal Outcomes Of The Freedom Covid Anticoagulation Trial

21.非重症住院Covid-19患者的抗凝策略：自由Covid抗凝试验的主要结果

22.The STELLAR Phase III Trial: A Study Of Sotatercept In Combination With Background Therapy For The Treatment Of Pulmonary Arterial Hypertension22.STELLAR III期试验：Sotatercept联合背景治疗用于肺动脉高压的疗效23.Efficacy And Safety Of The Oral PCSK9 Inhibitor, MK-0616, A Macrocyclic Peptide, In The Treatment Of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

23.口服PCSK9抑制剂MK-0616（一种大环肽）治疗高胆固醇血症的疗效和安全性：2b期随机安慰剂对照临床试验

Featured Clinical Research（FCR)

FCR Ⅰ

北京时间：3月5日2:00AM-3:15AM

24.Results From A Phase 2, Double-blind, Placebo-controlled Trial Evaluating The Efficacy And Safety Of Baxdrostat In Patients With Uncontrolled Hypertension

24.一项2期、双盲、安慰剂对照试验：Baxdrostat在未控制的高血压中的疗效和安全性

25.Effect Of Myocardial Viability, Percutaneous Coronary Intervention And Functional Recovery On Clinical Outcomes In The REVIVED-BCIS2 Randomized Trial

25.REVIVD-BCIS2随机试验：心肌存活率、经皮冠状动脉介入治疗和功能恢复对临床结果的影响

26.Ischemia And Viability Imaging In Heart Failure: The Alternative Imaging Modalities In Ischemic Heart Failure Trial

26.心力衰竭中的心肌缺血和存活成像：缺血性心力衰竭试验中的其他影像模态

27.Effect Of Evolocumab On Coronary Plaque Characteristics In Stable Coronary Artery Disease: A Multimodality Imaging Study (the Yellow III Study)

27.Evolocomab对稳定型冠心病中冠脉斑块特征的影响：一项多模态成像研究（Yellow III研究）

28.On-site Computed Tomography-derived Fractional Flow Reserve To Guide The Management Of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial

28.CT衍生的血流储备分数用于指导稳定型冠心病患者治疗：TARGET随机试验

FCR Ⅱ

北京时间：3月6日2:15AM-3:30AM

29.Atrial Pacing For Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial

29.保留射血分数的心力衰竭中的心房起搏：一项随机临床试验

30.Association Of A Low-carbohydrate High-fat (Ketogenic) Diet With Plasma Lipid Levels And Cardiovascular Risk In A Population-based Cohort

30.基于人群队列的低碳水化合物高脂肪（生酮）饮食与血脂水平和心血管风险的相关性

31.Pharmaco-invasive Reperfusion Strategy With Half-dose Tenecteplase In Older St-elevation Myocardial Infarction Patients

31.老龄ST段抬高型心肌梗死患者半剂量替奈普酶的药物干预性再灌注策略

32.Comparison Of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using The Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The Host-idea Randomized Clinical Trial

32.采用超薄支架和最新聚合物技术的当代药物洗脱支架进行冠状动脉介入治疗后3个月与12个月双重抗血小板治疗的比较

33.Safety And Efficacy Of Transcatheter Edge-to-Edge Mitral Repair In Degenerative Mitral Regurgitation: An Analysis Of The STS/ACC TVT Registry

33.经导管缘对缘二尖瓣修复术在退行性二尖瓣反流中的安全性和有效性：STS/ACC TVT注册研究的分析

FCR Ⅲ

北京时间：3月7日2:45AM-4:00AM

34.Lifelong Endurance Exercise And Its Relationship With Coronary Atherosclerosis

34.终身耐力运动及其与冠状动脉粥样硬化的关系

35.Residual Inflammatory Risk In Contemporary Statin Treated Patients: A Collaborative Analyses Of 31,197 Participants In The Prominent, Reduce-it, And Strength Trials

35.当代他汀类药物治疗下的残余炎症风险：对Prominent, Reduce-it和Strength系列试验中 31197名参与者的协作分析

36.Comparison Between Targeted Low-Density Lipoprotein Cholesterol Level Based Versus High-Intensity Statin Therapy In Patients With Coronary Artery Disease

36.冠心病患者中低密度脂蛋白胆固醇水平引导的与高强度他汀治疗的比较

37.Evaluation Of The Mechanism Of Benefit For Dapagliflozin In Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial

37.达格列净用于治疗射血分数保留的心力衰竭的获益机制评估：一项有创血流动力学随机试验

38.Safety And Efficacy Of Virtual Care Team Guided Therapeutic Optimization During Hospitalization In Patients With HFrEF:the IMPLEMENT-HF Study

38.HFrEF患者住院期间虚拟护理团队指导治疗优化的安全性和有效性：IMPLEMENT-HF研究

注：以上日程根据ACC官网公布结果整理，最终信息可能存在调整，更多资讯，请您持续关注！

延伸阅读

ACC2022｜重磅研究结果即将揭晓！严道医声网邀您持续关注

---

---

如期而至——ACC.20/WCC线上会议日程一览

· END ·

版权及免责声明：

严道医声网旨在搭建医学专家学术传播、为医者发声的媒体平台，所有经“严道医声网”微信公众号、APP及网站发布的文章，文内信息版权属于持有人，我们只提供传递信息之用。

1.严道医声网保留对内容进行技术性加工处理/删除的权利；

2.对转载、分享的内容，严道医声网会注明作者及来源；

3.所发布文章不代表严道医声网的立场/观点，如内容有误，欢迎指正；
4.针对无法确认出处的内容，若涉及版权、争议问题，无意侵犯到您的权益，烦请及时联系我们，给出内容所在网址并提供相关证明资料，我们通过核实后会立即更正或者删除有关内容。
本公众号不承担任何责任，并拥有对此声明的最终解释权。

获取更多资讯，点击 “阅读原文” 下载 “严道医声APP”